

*2008 CITR Annual Report Supplementary Materials*

*Table S1. CITR variables modeled for relationship to primary outcomes*

*Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions*

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b>Total</b>	264	100.0	41	100.0
<b><u>Cohort</u></b>				
<b>1999-2003</b>	139	52.7	18	43.9
<b>2004-2005</b>	112	42.4	19	46.3
<b>2006-2007</b>	13	4.9	4	9.8
<b><u>Recipient gender (1=M 2=F)</u></b>				
<b>Male</b>	91	34.5	16	39.0
<b>Female</b>	173	65.5	25	61.0
<b><u>Employment impacted by disease</u></b>				
<b><i>Missing</i></b>	20	7.6	4	9.8
<b>0</b>	189	71.6	20	48.8
<b><u>Employment impacted by disease</u></b>	55	20.8	17	41.5
<b><u>Baseline use of insulin pump (0=N 1=Y)</u></b>				
<b><i>Missing</i></b>	5	1.9	1	2.4
<b>N</b>	160	60.6	31	75.6
<b>Y</b>	99	37.5	9	22.0
<b><u>Intensive therapy duration</u></b>				
<b><i>Missing</i></b>	95	36.0	40	97.6
<b>Intensive yrs &lt;10</b>	52	19.7		
<b>10-&lt;25</b>	63	23.9	1	2.4
<b>&gt;=25</b>	54	20.5		
<b><u>Baseline GAD 65 autoantibodies (0,1)</u></b>				
<b><i>Missing</i></b>	105	39.8	19	46.3
<b>-</b>	103	39.0	15	36.6
<b>+</b>	56	21.2	7	17.1

**2008 CITR Annual Report Supplementary Materials**

**Table S1. CITR variables modeled for relationship to primary outcomes**

**Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions**

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Baseline IA-2 autoantibodies (0,1)</u></b>				
<i>Missing</i>	151	57.2	22	53.7
-	74	28.0	18	43.9
+	39	14.8	1	2.4
<b><u>Baseline insulin autoantibodies (0,1)</u></b>				
<i>Missing</i>	147	55.7	21	51.2
-	20	7.6	9	22.0
+	97	36.7	11	26.8
<b><u>Baseline total positive autoantobodies (0,1,2,3)</u></b>				
<i>Missing</i>	90	34.1	19	46.3
0	38	14.4	8	19.5
1	87	33.0	9	22.0
2	49	18.6	5	12.2
<b><u>Donor gender (1=M 1.5=Mix 2=F)</u></b>				
<i>Missing</i>	7	2.7		
Male	98	37.1	8	19.5
Mixed	112	42.4	27	65.9
Female	47	17.8	6	14.6
<b><u>Donor(s) Hispanic (0=N 1=Y)</u></b>				
N	229	86.7	36	87.8
Y	35	13.3	5	12.2
<b><u>Donor race (0=W 1=Non-white)</u></b>				
<i>Missing</i>	6	2.3		
White	202	76.5	35	85.4
Non-white	56	21.2	6	14.6

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Donor(s) blood type (1=A,B,AB 2=O)</u></b>				
<i>Missing</i>	14	5.3		
A,B,AB	147	55.7	24	58.5
O	103	39.0	17	41.5
<b><u>CVS death(s) (0=N 1=Y)</u></b>				
<i>Missing</i>	27	10.2	1	2.4
N	151	57.2	25	61.0
Y	86	32.6	15	36.6
<b><u>Donor(s) hx hypertension (0=N 1=Y)</u></b>				
<i>Missing</i>	25	9.5	1	2.4
N	111	42.0	17	41.5
Y	128	48.5	23	56.1
<b><u>Donor(s) alcohol history (0=N 1=Y)</u></b>				
<i>Missing</i>	42	15.9	2	4.9
N	150	56.8	21	51.2
Y	72	27.3	18	43.9
<b><u>Donor(s) diabetes (0=N 1=Y)</u></b>				
<i>Missing</i>	19	7.2	1	2.4
N	245	92.8	40	97.6
<b><u>Donor(s) given vasopressors (0=N 1=Y)</u></b>				
N	3	1.1	1	2.4
Y	261	98.9	40	97.6
<b><u>Donor transfused prior to hospitalization (0=N 1=Y)</u></b>				
<i>Missing</i>	6	2.3		
N	110	41.7	20	48.8

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
Y	148	56.1	21	51.2
<b><u>Donor(s) transfused in hospital (0=N 1=Y)</u></b>				
<i>Missing</i>	10	3.8		
N	226	85.6	37	90.2
Y	28	10.6	4	9.8
<b><u>Donor(s) given steroids (0=N 1=Y)</u></b>				
<i>Missing</i>	101	38.3	5	12.2
N	41	15.5	12	29.3
Y	122	46.2	24	58.5
<b><u>Donor(s) insulin (0=N 1=Y)</u></b>				
<i>Missing</i>	26	9.8	1	2.4
N	87	33.0	21	51.2
Y	151	57.2	19	46.3
<b><u>Any positive crossmatch (0=N 1=Y)</u></b>				
<i>Missing</i>	129	48.9	8	19.5
N	132	50.0	32	78.0
Y	3	1.1	1	2.4
<b><u>Procurement/infusion teams (0-Unrelated 1-Related)</u></b>				
<i>Missing</i>	13	4.9	1	2.4
Unrelated to processing/infusion team	124	47.0	23	56.1
Mixed	9	3.4		
Related to processing/infusion team	118	44.7	17	41.5
<b><u>Processing/infusion center (0-Unrelated 1-Related)</u></b>				
<i>Missing</i>	14	5.3		
0	31	11.7	1	2.4

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
Related	219	83.0	40	97.6
<u>Collagenase (1=Liberase alone 2=Other)</u>				
Missing	9	3.4		
Liberase HI	221	83.7	33	80.5
Serva	34	12.9	8	19.5
<u>Cultured &gt;6 hrs (0=N 1=Y)</u>				
Missing	9	3.4		
N	138	52.3	25	61.0
Y	117	44.3	16	39.0
<u>Genders match (0=N 1=Y)</u>				
N	198	75.0	34	82.9
Y	66	25.0	7	17.1
<u>Donor(s) CMV+ / Recipient CMV- (0=N 1=Y)</u>				
Missing	22	8.3	1	2.4
N	136	51.5	26	63.4
Y	106	40.2	14	34.1
<u>Pancreas preservation (1-UW 2-2L 3-Both)</u>				
Missing	38	14.4	2	4.9
UW	118	44.7	24	58.5
Other	88	33.3	11	26.8
UW+Other	20	7.6	4	9.8
<u>Recipient insulin day 0 (0=N 1=Y)</u>				
Missing	52	19.7	5	12.2
N	76	28.8	5	12.2
Y	136	51.5	31	75.6

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Viability &gt; 87% (0=N 1=Y)</u></b>				
<i>Missing</i>	21	8.0		
<87%	13	4.9	1	2.4
>87%	230	87.1	40	97.6
<b><u>Insulin content</u></b>				
<i>Missing</i>	132	50.0	25	61.0
<b><u>Insulin content</u></b>	29	11.0	4	9.8
3.-<5.0	28	10.6	1	2.4
>=5.0	75	28.4	11	26.8
<b><u>Isletsize (0-small 1-large)</u></b>				
<i>Missing</i>	52	19.7	7	17.1
Small	87	33.0	12	29.3
Large	125	47.3	22	53.7
<b><u>Sirolimus</u></b>				
<i>Missing</i>	5	1.9	1	2.4
N	12	4.5	8	19.5
Y	247	93.6	32	78.0
<b><u>Tacrolimus</u></b>				
<i>Missing</i>	3	1.1	1	2.4
N	15	5.7	3	7.3
Y	246	93.2	37	90.2
<b><u>DSG</u></b>				
<i>Missing</i>	16	6.1	1	2.4
N	243	92.0	40	97.6
Y	5	1.9		

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Everolimus</u></b>				
<i>Missing</i>	16	6.1	1	2.4
<b>N</b>	242	91.7	40	97.6
<b>Y</b>	6	2.3		
<b><u>Thymoglobulin</u></b>				
<i>Missing</i>	12	4.5	1	2.4
<b>N</b>	222	84.1	39	95.1
<b>Y</b>	30	11.4	1	2.4
<b><u>Daclizumab</u></b>				
<i>Missing</i>	6	2.3	1	2.4
<b>N</b>	40	15.2	3	7.3
<b>Y</b>	218	82.6	37	90.2
<b><u>h-OOKT3g-1</u></b>				
<i>Missing</i>	14	5.3	1	2.4
<b>N</b>	242	91.7	40	97.6
<b>Y</b>	8	3.0		
<b><u>Basiliximab</u></b>				
<i>Missing</i>	14	5.3	1	2.4
<b>N</b>	234	88.6	38	92.7
<b>Y</b>	16	6.1	2	4.9
<b><u>Alemtuzumab</u></b>				
<i>Missing</i>	13	4.9	1	2.4
<b>N</b>	232	87.9	40	97.6
<b>Y</b>	19	7.2		

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Infliximab</u></b>				
<i>Missing</i>	16	6.1	1	2.4
<b>N</b>	229	86.7	37	90.2
<b>Y</b>	19	7.2	3	7.3
<b><u>Etanercept</u></b>				
<i>Missing</i>	16	6.1	1	2.4
<b>N</b>	196	74.2	34	82.9
<b>Y</b>	52	19.7	6	14.6
<b><u>Cyclosporin</u></b>				
<i>Missing</i>	13	4.9	1	2.4
<b>N</b>	245	92.8	38	92.7
<b>Y</b>	6	2.3	2	4.9
<b><u>Poly T-cell depleting</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	218	82.6	38	92.7
<b>Y</b>	24	9.1		
<b><u>Mono T-cell depleting</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	228	86.4	38	92.7
<b>Y</b>	14	5.3		
<b><u>Anti-II2</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	35	13.3	3	7.3
<b>Y</b>	207	78.4	35	85.4

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Anti-CD3</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	236	89.4	38	92.7
<b>Y</b>	6	2.3		
<b><u>TNF blocker</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	186	70.5	30	73.2
<b>Y</b>	56	21.2	8	19.5
<b><u>Deoxysperqualin</u></b>				
<i>Missing</i>	16	6.1	3	7.3
<b>N</b>	244	92.4	38	92.7
<b>Y</b>	4	1.5		
<b><u>Calcineurin inhibitor</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	10	3.8		
<b>Y</b>	232	87.9	38	92.7
<b><u>Sirolimus or Everolimus</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	15	5.7	8	19.5
<b>Y</b>	227	86.0	30	73.2
<b><u>MMF or mycophenolic acid</u></b>				
<i>Missing</i>	22	8.3	3	7.3
<b>N</b>	204	77.3	25	61.0
<b>Y</b>	38	14.4	13	31.7

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Prednisone, Methylprednisolone, or other steroid</u></b>				
<i>Missing</i>	16	6.1	3	7.3
<b>N</b>	232	87.9	30	73.2
<b>Y</b>	16	6.1	8	19.5
<b><u>Poly or mono T-cell AB + calc inh + (mtor OR inosine)</u></b>				
<b>N</b>	251	95.1	41	100.0
<b>Y</b>	13	4.9		
<b><u>Poly or mono T-cell AB + TNF-alpha ant + calc inh + (mtor OR inosine)</u></b>				
<b>N</b>	256	97.0	41	100.0
<b>Y</b>	8	3.0		
<b><u>Monoclonal anti-IL2R + calc inh + (mtor OR inosine)</u></b>				
<b>N</b>	111	42.0	19	46.3
<b>Y</b>	153	58.0	22	53.7
<b><u>Monoclonal anti-IL2R + TNF-alpha ant + calc inh + (mtor OR inosine)</u></b>				
<b>N</b>	228	86.4	34	82.9
<b>Y</b>	36	13.6	7	17.1
<b><u>Reexposed to A locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	185	70.1	27	65.9
<b>Y</b>	70	26.5	14	34.1
<b><u>Reexposed to B locus mismatch</u></b>				
.	9	3.4		
<b>N</b>	216	81.8	32	78.0
<b>Y</b>	39	14.8	9	22.0

2008 CITR Annual Report Supplementary Materials

Table S1. CITR variables modeled for relationship to primary outcomes

Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions

	Type of transplant			
	Islet Alone		Islet after Kidney	
	N	%	N	%
<b><u>Reexposed to DR locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	195	73.9	25	61.0
<b>Y</b>	60	22.7	16	39.0
<b><u>Reexposed to DQ locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	195	73.9	25	61.0
<b>Y</b>	60	22.7	16	39.0
<b><u>Reexposed to Class I locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	177	67.0	25	61.0
<b>Y</b>	78	29.5	16	39.0
<b><u>Reexposed to Class II locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	200	75.8	23	56.1
<b>Y</b>	55	20.8	18	43.9
<b><u>Reexposed to A/B/DR locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	171	64.8	20	48.8
<b>Y</b>	84	31.8	21	51.2
<b><u>Reexposed to A/B/DR/DQ locus mismatch</u></b>				
<i>Missing</i>	9	3.4		
<b>N</b>	198	75.0	21	51.2
<b>Y</b>	57	21.6	20	48.8

*CITR variables modeled for relationship to primary outcomes*

*Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions*

	Type of transplant											
	Islet Alone						Islet after Kidney					
	N	Min	P25	Median	P75	Max	N	Min	P25	Median	P75	Max
Recipient age (years)	264.0	2.0	3.7	4.4	5.1	6.7	41.0	3.4	4.2	4.5	5.1	6.0
Diabetes Duration (years)	264.0	0.2	1.9	2.9	3.6	5.4	41.0	1.8	2.9	3.1	3.8	4.8
Months on waitlist	258.0	0.0	2.2	5.6	12.4	49.6	38.0	0.0	1.2	3.8	14.0	43.5
Baseline daily insulin use (Units)	258.0	1.2	2.8	3.5	4.4	8.6	40.0	1.9	2.7	3.4	5.0	7.0
Baseline weight (10-kg)	257.0	3.5	6.0	6.5	7.4	9.8	40.0	4.3	5.6	6.2	6.7	8.9
Baseline PRA (%)	242.0	0.0	0.0	0.0	0.0	86.0	33.0	0.0	0.0	0.0	0.0	5.0
Baseline BMI	255.0	17.9	22.1	23.5	25.7	31.6	40.0	15.4	20.8	22.7	24.5	27.7
Baseline number of daily insulin injections	174.0	0.0	3.0	4.0	4.0	13.0	29.0	0.0	3.0	4.0	5.0	7.0
Baseline use of insulin pump or >=3 insulin inject	259.0	0.0	1.0	1.0	1.0	1.0	40.0	0.0	1.0	1.0	1.0	1.0
Years prior to first inf using ins pump or >= 3 in	186.0	0.0	5.0	14.0	28.0	50.0	8.0	0.0	0.0	0.0	0.0	10.0
Baseline HbA1c (%)	251.0	4.8	6.7	7.5	8.5	12.2	39.0	5.9	6.9	7.6	8.5	10.5
Baseline fasting glucose (mg/dL)	247.0	3.5	9.7	15.2	22.7	56.0	38.0	4.4	10.3	16.5	21.1	56.8
Baseline C-peptide (ng/mL)	251.0	0.0	0.0	0.0	0.0	1.6	37.0	0.0	0.0	0.0	0.0	0.5
Donor age (x10 yrs)	251.0	0.9	5.2	8.4	10.4	20.1	40.0	2.6	5.3	9.4	11.1	19.8
Donor(s) weight (10-kg)	255.0	2.5	11.8	16.7	21.8	36.0	41.0	7.9	14.4	16.3	21.9	31.6
Donor(s) height (cm)	255.0	137.0	190.5	345.5	365.8	705.0	41.0	170.0	327.0	347.9	363.2	704.0
Donor(s) BSA	255.0	1.0	2.4	4.0	4.7	8.2	41.0	2.0	3.6	4.0	5.2	7.2
Donor(s) BMI	255.0	13.3	40.3	84.5	110.3	221.5	41.0	24.7	72.7	84.2	127.1	173.8
Donor(s) creatinine	231.0	0.4	1.4	1.9	2.8	12.8	41.0	0.6	1.5	2.0	2.7	4.8
Donor(s) BUN	165.0	4.0	17.0	26.0	39.0	93.0	41.0	5.0	19.5	28.3	42.0	84.0
Donor(s) bilirubin	172.0	0.2	0.9	1.5	2.2	8.8	40.0	0.3	1.1	1.4	2.1	4.2
Donor(s) AST	186.0	13.0	52.0	81.8	141.5	4610.0	40.0	11.0	52.8	99.0	163.3	1868.0
Donor(s) ALT	187.0	10.0	37.0	67.0	117.0	3471.0	40.0	13.0	52.5	78.5	115.0	1347.0
Donor(s) serum lipase	226.0	0.0	0.0	1.0	2.9	30.4	35.0	0.0	1.0	1.5	3.0	7.0
Donor(s) serum amylase	233.0	0.0	2.0	3.0	6.0	81.0	41.0	1.0	2.0	3.0	5.0	39.5
Donor(s) pre-insulin glucose	251.0	0.6	1.4	2.3	3.0	6.6	41.0	1.2	2.0	2.4	2.9	5.4

*CITR variables modeled for relationship to primary outcomes*

*Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions*

	Type of transplant											
	Islet Alone						Islet after Kidney					
	N	Min	P25	Median	P75	Max	N	Min	P25	Median	P75	Max
Max donor(s) glucose (mg/dL)	239.0	103.0	296.0	421.0	551.0	1201.0	41.0	210.5	393.0	438.0	564.0	1094.0
Culture time (hrs)	253.0	0.0	0.0	19.5	49.0	134.0	37.0	0.0	0.0	16.1	48.0	101.0
Donor(s)-recipient age difference (x10-yrs)	251.0	-7.4	-1.7	-0.1	1.6	7.2	40.0	-6.8	-1.7	-0.2	1.3	6.6
Donor(s)-recipient BMI difference (x10)	248.0	-1.6	0.3	1.0	1.7	4.6	40.0	-1.3	0.5	1.4	2.0	6.1
Time from cross clamp to panc recovery (hrs)	203.0	0.0	0.6	1.1	1.6	6.5	39.0	0.2	0.8	1.6	2.0	5.0
Time from admission to death (hrs)	219.0	-13.2	29.7	57.7	117.3	638.8	31.0	4.7	44.4	75.5	117.9	279.3
Death to pancreas recovery (hrs)	202.0	0.0	0.4	0.6	0.8	1.8	38.0	0.1	0.4	0.6	0.7	2.2
Recovery to transplant (hrs)	204.0	0.2	22.9	48.7	74.9	231.3	39.0	4.8	29.4	46.4	81.1	170.0
Death to cross-clamp (hrs)	252.0	0.1	0.2	0.3	0.5	2.2	40.0	0.1	0.3	0.3	0.4	1.3
Death to transplant (hrs)	254.0	14.8	59.5	90.1	136.4	421.6	40.0	23.3	60.4	82.7	137.7	268.0
Cold ischemia time (hrs)	256.0	1.1	7.7	12.9	19.0	45.6	40.0	4.9	8.7	12.4	15.6	28.7
Embedded islets (%)	179.0	0.0	6.0	20.0	45.0	163.0	12.0	0.0	6.5	17.5	32.5	61.0
Stimulation index	244.0	0.1	3.1	4.7	7.5	33.0	35.0	0.8	2.7	3.8	6.6	12.4
Stimulation index <2/2-3.5/>=3.5	244.0	1.0	2.0	3.0	3.0	3.0	35.0	1.0	2.0	3.0	3.0	3.0
Islet Viability (%)	243.0	79.0	98.0	181.0	197.0	398.0	41.0	86.0	175.0	188.0	194.0	366.0
Total beta cells (1000s)	112.0	0.0	0.2	0.4	0.8	2.0	11.0	0.0	0.4	0.7	1.0	1.3
Total beta cells/kg donor	109.0	0.0	0.0	0.0	0.1	0.2	11.0	0.0	0.1	0.1	0.1	0.1
Total insulin content of islets	132.0	0.0	3.4	5.8	8.8	26.9	16.0	0.1	3.4	6.8	11.2	15.2
Total endotoxin infused	227.0	0.0	0.0	0.0	0.1	0.6	33.0	0.0	0.0	0.0	0.1	0.3
Total endotoxin infused/kg donor	221.0	0.0	0.3	1.9	7.5	82.7	33.0	0.0	0.1	1.2	6.7	35.6
Endotoxin/kg <0.6/.06-3.0/>=3.0	220.0	1.0	2.0	2.0	3.0	3.0	33.0	1.0	2.0	2.0	3.0	3.0
Total IEQs at time of islet count (1000s)	259.0	0.2	0.6	0.8	1.0	2.9	41.0	0.2	0.7	0.9	1.0	1.5
Total islet particles infused (1000s)	212.0	0.1	0.5	0.7	1.0	1.9	34.0	0.1	0.6	0.7	1.0	1.4
Total volume infused over all infusions (ml)	243.0	1.0	6.5	13.0	21.9	61.8	30.0	2.1	7.8	16.5	20.0	65.6
Cumulative IEQs infused (1000s)	261.0	0.2	0.6	0.8	1.0	2.9	39.0	0.2	0.6	0.8	1.0	1.5
Cumulative IEQs infused/kg recipient (100s)	254.0	2.7	8.7	11.7	15.0	50.3	38.0	4.6	9.2	13.2	16.0	27.3

*CITR variables modeled for relationship to primary outcomes*

*Recipient values at pre-infusion, donor and islet factors cumulated or averaged over all infusions*

	Type of transplant											
	Islet Alone						Islet after Kidney					
	N	Min	P25	Median	P75	Max	N	Min	P25	Median	P75	Max
<b>IEQ/islet particle ratio</b>	212.0	0.5	0.9	1.1	1.4	3.3	34.0	0.7	0.8	1.1	1.4	3.6
<b>Number of A locus mismatches</b>	185.0	0.0	2.0	2.0	4.0	7.0	34.0	1.0	2.0	3.0	4.0	7.0
<b>Number of B locus mismatches</b>	186.0	0.0	2.0	3.0	4.0	8.0	33.0	1.0	3.0	4.0	4.0	8.0
<b>Number of DR locus mismatches</b>	169.0	0.0	2.0	3.0	4.0	8.0	32.0	0.0	2.0	3.0	4.0	7.0
<b>Number of DQ locus mismatches</b>	79.0	0.0	1.0	1.0	2.0	6.0	18.0	0.0	2.0	2.5	3.0	3.0
<b>Number of Class I locus mismatches</b>	181.0	1.0	4.0	6.0	8.0	15.0	33.0	2.0	5.0	6.0	8.0	14.0
<b>Number of Class II locus mismatches</b>	71.0	0.0	3.0	4.0	6.0	14.0	18.0	0.0	5.0	6.0	7.0	9.0
<b>Number of A/B/DR locus mismatches</b>	162.0	3.0	5.0	9.0	12.0	22.0	31.0	3.0	7.0	9.0	12.0	20.0
<b>Number of A/B/DR/DQ locus mismatches</b>	68.0	3.0	6.0	9.5	13.0	25.0	17.0	3.0	10.0	12.0	16.0	21.0